Skip to content

Cytokinetics CYTK Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-605.1%+2,338pp-695.4%+2,207pp-656.9%+15,641pp-638%+15,510pp-2,943.3%+10,329pp
Net margin-784%+2,417pp-891.6%+2,300pp-862.2%+17,044pp-707.2%+16,692pp-3,201.5%+10,940pp
Efficiency
Asset turnover0.1×+0.1×0.1×0.0×0.1×+0.1×0.1×+0.1×0.0×
Liquidity
Current ratio4.2×-1.8×4.5×-1.6×6.9×-2.4×6.8×-3.6×-1.2×
Per Share
Book value per share-$6.71-198%-$5.49-354%-$4.34-3,575%-$3.09-411%-$2.25+42.2%
Valuation
Market capitalization$8.12B+70.6%$7.77B+39.9%$6.58B+5.9%$3.99B-37.2%$4.76B-34.1%
Price / sales76.7×-171×88.2×-212×75.4×-1,855×46.5×-1,979×247.6×-1,677×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Cytokinetics's ratios come from?
Every ratio is computed from Cytokinetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.